English home · HPV and cervical screening · Türkçe
When a Pap smear says HSIL, I explain the finding seriously without equating it with cancer. HSIL suggests high-grade changes in the sampled cells. It is not, by itself, a cancer diagnosis, but it may indicate a lesion that needs assessment and treatment. Understanding what each test shows helps make the next decision clearer.
What does HSIL mean?
HSIL stands for high-grade squamous intraepithelial lesion. On a Pap smear it describes how the cells look under a microscope. “High-grade” does not describe a cancer stage. A cytology result cannot be translated into “stage two” or “stage three” cancer. Diagnosis, lesion grade and cancer stage are different concepts.
HSIL may also appear on a biopsy report, where it describes a tissue finding. In that setting, whether the lesion is specified as CIN 2 or CIN 3 matters for management. I first establish whether the report concerns sampled cells or a tissue biopsy. The same abbreviation does not make the two reports identical.
What is the relationship with HPV?
Persistent high-risk HPV infection is associated with high-grade cervical changes. An HPV result and genotype information contribute to risk assessment. However, a negative HPV test is not enough to dismiss HSIL. Cell testing and HPV testing provide different information, and both need to be considered.
The result cannot establish when infection began or who transmitted it. Previous negative results are useful for understanding the history, but they do not mean that the current finding can be ignored. I keep the discussion focused on clarifying the present abnormality rather than assigning blame.
Colposcopy, biopsy and possible treatment
Colposcopy and biopsy from relevant areas are part of the assessment for many patients with HSIL. The examination considers the cervical surface and whether the area of concern can be fully seen. Biopsy helps establish the tissue finding behind the cytology result. Mention HSIL when arranging the appointment.
Current guidelines also allow discussion of excisional treatment without a preceding biopsy diagnosis for selected nonpregnant adults who meet defined high-risk criteria. This does not mean that everyone with HSIL should undergo an immediate procedure. Age, HPV type, screening history, future pregnancy plans and the possible effects of treatment must be considered together.
When appropriate, LEEP or cone excision removes tissue for pathological examination as well as treating the lesion. HSIL alone does not mean the uterus must be removed. The reason for any proposed procedure, alternatives and the follow-up plan should be explained separately.
What if the smear says HSIL but biopsy shows CIN 1?
Different results do not automatically mean that one laboratory made an error. A biopsy samples a specific area, while cytology examines a different collection of cells. Adequate visibility, any canal sample and the pathology details all matter. It is not appropriate to select the low-grade result and disregard the high-grade smear.
The reports may need to be reviewed together before choosing surveillance or a diagnostic excision. I explain why a proposed step is necessary and what uncertainty it is intended to resolve. The CIN and biopsy guide gives further context, but an online explanation cannot select the right option for an individual patient.
How do age and pregnancy affect care?
ASCCP guidance recommends colposcopy for HSIL in patients younger than 25 and does not recommend treatment without biopsy confirmation in that age group. The aim is to maintain necessary assessment while avoiding unnecessary treatment. The biopsy grade then helps determine the next step.
HSIL is also assessed during pregnancy. Colposcopy and a clinically indicated targeted biopsy may be performed, but ECC is not used. Expedited treatment is not used during pregnancy. When cancer is not suspected, treatment of a precancerous lesion is generally planned after delivery with appropriate surveillance in the meantime.
When should you seek assessment?
Arrange a review promptly after receiving the HSIL report. Lack of symptoms does not make the finding unimportant. Mention bleeding after sex, between periods or after menopause. Heavy bleeding, faintness or severe pain may need urgent medical assessment rather than a routine appointment.
I recommend bringing earlier Pap and HPV results, biopsy reports and any LEEP pathology. If treatment is performed, the final pathology result and later surveillance still need review. Treatment does not guarantee that HPV has disappeared or that future tests are unnecessary. Keep the written follow-up plan and establish who will explain each new result, especially when continuing care between countries.
Frequently asked questions
Is HSIL a diagnosis of cancer?
No. It is a high-grade cell finding that needs further assessment to identify the underlying tissue change.
Does every HSIL result require LEEP?
Not automatically. Age, HPV, pregnancy, colposcopy and pathology affect the decision. Selected high-risk nonpregnant adults may discuss direct excision.
Does a negative HPV result invalidate HSIL?
No. HSIL still needs assessment. The HPV test and the Pap smear answer different questions.
Will follow-up be needed after LEEP?
Yes. Pathology review and HPV-based surveillance remain important. The timing depends on the findings before and after treatment.